Keen interest in FcRn biology has been boosted by the findings demonstrating that blocking IgG binding to FcRn results in beneficial therapeutic effects in IgG-mediated autoimmune diseases, such as MG, CIDP and ITP (19–21). This evidence concerns the gene FCGRT and autoimmune thrombocytopenic purpura.